Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYLIA 7/7/7 vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Oral contraception
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (Cr Cl <30 m L/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Ethinyl estradiol primarily via CYP3A4; norethindrone via reduction and sulfate conjugation.
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
98% bound to albumin and alpha-1-acid glycoprotein.
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
0.6 L/kg (range 0.4–0.8 L/kg), indicating extensive tissue distribution.
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Oral: 75% (range 60–85%), with food decreasing absorption by 20%.
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
No specific dose adjustment guidelines available; use caution in patients with renal impairment. Contraindicated in severe renal disease or renal failure due to potential hormonal metabolism alterations.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Contraindicated in Child-Pugh class B or C cirrhosis or active liver disease. For mild hepatic impairment (Child-Pugh A), use caution and monitor for adverse effects; no specific dose reduction established.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, same dosing as adults; safety and efficacy established in females of reproductive age.
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke due to increased cardiovascular risk.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events; women over 35 who smoke should not use combination oral contraceptives.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders risk,Cerebrovascular disease,Myocardial infarction,Hepatic neoplasia,Gallbladder disease,Hypertension,Diabetes/glucose intolerance,Headache/migraine,Bleeding irregularities
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Thrombophlebitis/thromboembolic disorders,Cerebrovascular/coronary artery disease,Known/suspected pregnancy,Undiagnosed abnormal genital bleeding,Known/suspected breast carcinoma,Hepatic adenoma/carcinoma,Jaundice/cholestatic jaundice with prior pill use,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women >35
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
No significant food interactions. Grapefruit juice may increase estrogen levels; avoid large amounts. Maintain consistent dietary habits to avoid hormone fluctuations.
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
NYLIA 7/7/7 contains ethinyl estradiol and norethindrone. First trimester: Not associated with major teratogenic effects in humans based on epidemiological data. Second and third trimesters: Avoid use due to potential adverse effects such as fetal genital abnormalities (including hypospadias and feminization of male fetuses) and other adverse outcomes associated with sex hormone exposure during pregnancy.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Ethinyl estradiol and norethindrone are excreted in breast milk in small amounts. M/P ratio not well-established; estrogens may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Alternative contraception advised.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
NYLIA 7/7/7 is contraindicated in pregnancy; no dose adjustment recommended as use should be discontinued immediately upon pregnancy diagnosis. No pharmacokinetic data to support dose changes in pregnancy.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
NYLIA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Start on the first day of menstruation; no back-up contraception needed if started correctly. Missed pills increase pregnancy risk; if one pill missed, take as soon as remembered and continue pack; if two or more missed, use back-up contraception for 7 days. Monitor for thromboembolic events, especially in smokers over 35. Consider drug interactions with rifampin, anticonvulsants, and some antibiotics.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Take one pill daily at the same time each day.,If you miss a pill, follow the instructions in the package insert.,Use back-up contraception (like condoms) if you start the pack late or miss multiple pills.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical attention if you experience severe headache, chest pain, or leg swelling.,This medication does not protect against HIV or other STDs.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYLIA 7/7/7 vs ESTARYLLA, answered by our medical review team.
NYLIA 7/7/7 is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYLIA 7/7/7 and ESTARYLLA depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYLIA 7/7/7 is: One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYLIA 7/7/7 and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYLIA 7/7/7 is classified as Category C. NYLIA 7/7/7 contains ethinyl estradiol and norethindrone. First trimester: Not associated with major teratogenic effects in humans based on epidemiological data. Second and third t. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.